Measuring side effects after radiotherapy for pharynx cancer

Acta Oncologica

Volumn 46, Issue 8, 2007, Pages 1051-1063

  Jensen, Kenneth ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SURVIVAL; CLINICAL ASSESSMENT; COMPUTER ASSISTED RADIOTHERAPY; CORRELATION ANALYSIS; DYSPHAGIA; FUNCTIONAL STATUS; HUMAN; MEASUREMENT; PHARYNX CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; REVIEW; TOOTH DISEASE; VALIDATION STUDY; XEROSTOMIA;

COMBINED MODALITY THERAPY; HUMANS; MODELS, BIOLOGICAL; PHARYNGEAL NEOPLASMS; QUALITY OF LIFE; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; TOOTH DISEASES; XEROSTOMIA;

EID: 35848962306     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701481547     Document Type: Review

References (113)

1. Bentzen SM, Dorr W, Anscher MS, Denham JW, Hauer-Jensen M, Marks LB, et al. Normal tissue effects: Reporting and analysis. Semin Radiat Oncol 2003;13:189-202.
2. Hakim SG, Jacobsen HC, Hermes D, Kosmehl H, Lauer I, Nadrowitz R, et al. Early immunohistochemical and functional markers indicating radiation damage of the parotid gland. Clin Oral Investig 2004;8:30-5.
3. Steel GG, Begg AC, Stewart FA, van der Kogel AJ, Joiner MC, McMillan TJ, et al. Basic Clinical Radiobiology, 3rd ed. London: Arnold; 2002. p. 26.
4. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-22.
5. Lyman JT. Normal tissue complication probabilities: Variable dose per fraction. Int J Radiat Oncol Biol Phys 1992;22:247-50.
6. Kwa SL, Theuws JC, Wagenaar A, Damen EM, Boersma LJ, Baas P, et al. Evaluation of two dose-volume histogram reduction models for the prediction of radiation pneumonitis. Radiother Oncol 1998;48:61-9.
7. Niemierko A, Goitein M. Calculation of normal tissue complication probability and dose-volume histogram reduction schemes for tissues with a critical element architecture. Radiother Oncol 1991;20:166-76.
8. Kutcher GJ. Quantitative plan evaluation: TCP/NTCP models. Front Radiat Ther Oncol 1996;29:67-80.
9. Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu CS, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 2006.
10. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
11. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: Comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 2003;55:93-8.
12. Aviv JE, Kaplan ST, Thomson JE, Spitzer J, Diamond B, Close LG. The safety of flexible endoscopic evaluation of swallowing with sensory testing (FEESST): An analysis of 500 consecutive evaluations. Dysphagia 2000;15:39-44.
13. Aviv JE. Prospective, randomized outcome study of endoscopy versus modified barium swallow in patients with dysphagia. Laryngoscope 2000;110:563-74.
14. Wu CH, Hsiao TY, Chen JC, Chang YC, Lee SY. Evaluation of swallowing safety with fiberoptic endoscope: Comparison with videofluoroscopic technique. Laryngoscope 1997;107:396-401.
15. Grau C, Moller K, Overgaard M, Overgaard J, Elbrond O. Auditory brain stem responses in patients after radiation therapy for nasopharyngeal carcinoma. Cancer 1992;70:2396-401.
16. Pauloski BR, Rademaker AW, Logemann JA, Colangelo LA. Speech and swallowing in irradiated and nonirradiated postsurgical oral cancer patients. Otolaryngol Head Neck Surg 1998;118:616-24.
17. Cheung M, Chan AS, Law SC, Chan JH, Tse VK. Cognitive function of patients with nasopharyngeal carcinoma with and without temporal lobe radionecrosis. Arch Neurol 2000;57:1347-52.
18. Buus S, Grau C, Munk OL, Rodell A, Jensen K, Mouridsen K, Keiding S. Individual radiation response of parotid glands investigated by dynamic 11C-methionine PET. Radiother Oncol 2006;78:262-9.
19. van Acker F, Flamen P, Lambin P, Maes A, Kutcher GJ, Weltens C, et al. The utility of SPECT in determining the relationship between radiation dose and salivary gland dysfunction after radiotherapy. Nucl Med Commun 2001;22:225-31.
20. Langmore SE. Evaluation of oropharyngeal dysphagia: Which diagnostic tool is superior? Curr Opin Otolaryngol Head Neck Surg 2003;11:485-9.
21. Dische S, Warburton MF, Jones D, Lartigau E. The recording of morbidity related to radiotherapy. Radiother Oncol 1989;16:103-8.
22. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
23. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6.
24. Pavy JJ, Denekamp J, Letschert J, Littbrand B, Mornex F, Bernier J, et al. EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Radiother Oncol 1995;35:11-5.
25. Rubin P, Constine LS, III, Fajardo LF, Phillips TL, Wasserman TH. EORTC Late Effects Working Group. Overview of late effects normal tissues (LENT) scoring system. Radiother Oncol 1995;35:9-10.
26. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003;20;362:933-40.
27. Jensen K, Overgaard M, Grau C. Morbidity after Ipsilateral radiotherapy for oropharyngeal cancer. Radiother Oncol 2007. In press.
28. Skladowski K, Maciejewski B, Golen M, Tarnawski R, Slosarek K, Suwinski R, et al. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: Longterm results of phase III clinical trial. Int J Radiat Oncol Biol Phys 2006;66:706-13.
29. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;44:123-36.
30. Kemmler G, Holzner B, Kopp M, Dunser M, Margreiter R, Greil R, et al. Comparison of two quality-of-life instruments for cancer patients: The functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol 1999;17:2932-40.
31. Jensen K, Lambertsen K, Torkov P, Dahl M, Jensen AB, Grau C. Patient assessed symptoms are poor predictors of objective findings. Results from a cross sectional study in patients treated with radiotherapy for pharynx cancer. Acta Oncol. In press.
32. Eisbruch A. Dysphagia and aspiration following chemoirradiation of head and neck cancer: Major obstacles to intensification of therapy. Ann Oncol 2004;15:363-4.
33. Jensen K, Lambertsen K, Grau C. Late swallowing dysfunction and dysphagia after radiotherapy for pharynx cancer. Frequency, intensity and correlation with dose and volume parameters. Radiother Oncol 2007. In press.
34. Nguyen NP, Frank C, Moltz CC, Vos P, Smith HJ, Bhamidipati PV, et al. Aspiration rate following chemoradiation for head and neck cancer: An underreported occurrence. Radiother Oncol 2006.
35. Campbell BH, Spinelli K, Marbella AM, Myers KB, Kuhn JC, Layde PM. Aspiration, weight loss, and quality of life in head and neck cancer survivors. Arch Otolaryngol Head Neck Surg 2004;130:1100-3.
36. Robbins KT. Barriers to winning the battle with head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:4-5.
37. Lazarus CL. Effects of radiation therapy and voluntary manoeuvres on swallow functioning in head and neck cancer patients. Clin Commun Disord 1993;3:11-20.
38. Shaker R, Easterling C, Kern M, Nitschke T, Massey B, Daniels S, et al. Rehabilitation of swallowing by exercise in tube-fed patients with pharyngeal dysphagia secondary to abnormal UES opening. Gastroenterology 2002;122:1314-21.
39. Wu CH, Hsiao TY, Ko JY, Hsu MM. Dysphagia after radiotherapy: Endoscopic examination of swallowing in patients with nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol 2000;109:320-5.
40. Parise JO, Miguel RE, Gomes DL, Menon AD, Hashiba K. Laryngeal sensitivity evaluation and dysphagia: Hospital Sirio-Libanes experience. Sao Paulo Med J 2004;122:200-3.
41. Hughes PJ, Scott PM, Kew J, Cheung DM, Leung SF, Ahuja AT, et al. Dysphagia in treated nasopharyngeal cancer. Head Neck 2000;22:393-7.
42. Smith RV, Goldman SY, Beitler JJ, Wadler SS. Decreased short- and long-term swallowing problems with altered radiotherapy dosing used in an organ-sparing protocol for advanced pharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:831-6.
43. Eisbruch A, Schwartz M, Rasch C, Vineberg K, Damen E, Van As CJ, et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: Which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 2004;60:1425-39.
44. Feng FY, Kim HM, Lyden TH, Haxer MJ, Feng M, Worden FP, Chepeha DB, Eisbruch A. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: Early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 2007 Jun 6; [Epub ahead of print].
45. Simmons JR, Dornfeld K, Karnell M, Funk G, Yao M, Wacha B, et al. Radiation doses to structures within and adjacent to the larynx are correlated with long term diet and speech related quality of life. Int J Radiat Oncol Biol Phys 2005;63:S132.
46. Levendag P, Teguh D, van Rooil P, Voet P, van der Est H, Heijmen B, et al. Dysphagia related quality of life patients with cancer in the oropharynx is significantly affected by radiation therapy dose received by the superior- and middle constrictor mucle: A dose effect relationship. Radiother Oncol 2006;81(Suppl 1):S337-8.
47. Mittal BB, Pauloski BR, Haraf DJ, Pelzer HJ, Argiris A, Vokes EE, et al. Swallowing dysfunction-preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: A critical review. Int J Radiat Oncol Biol Phys 2003;57:1219-30.
48. Rosenthal DI, Lewin JS, Eisbruch A. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 2006;24:2636-43.
49. Carnaby-Mann G. Preventive exercise for dysphagia following head and neck cancer. Dysphagia Symposium, EGDG Meeting 2006, Sweden, 2006. p 46-7. (Abstract).
50. Jensen AB, Hansen O, Jorgensen K, Bastholt L. Influence of late side-effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer. Acta Oncol 1994;33:487-91.
51. Bardow A, ten Cate JM, Nauntofte B, Nyvad B. Effect of unstimulated saliva flow rate on experimental root caries. Caries Res 2003;37:232-6.
52. de Arruda FF, Puri DR, Zhung J, Narayana A, Wolden S, Hunt M, et al. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: The memorial sloan-kettering cancer center experience. Int J Radiat Oncol Biol Phys 2005.
53. Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002;53:12-22.
54. Blanco AI, Chao KS, El N, I, Franklin GE, Zakarian K, Vicic M, et al. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:1055-69.
55. Jellema AP, Doornaert P, Slotman BJ, Leemans CR, Langendijk JA. Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy? Radiother Oncol 2005;77:164-71.
56. Eisbruch A, Ten Haken RK, Kim HM, Marsh LH, Ship JA. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 1999;45:577-87.
57. Saarilahti K, Kouri M, Collan J, Kangasmaki A, Atula T, Joensuu H, Tenhunen M. Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer. Radiother Oncol 2006;78:270-5.
58. Chambers MS, Garden AS, Kies MS, Martin JW. Radiation-induced Xerostomia in patients with head and neck cancer: Pathogenesis, impact on quality of life, and management. Head Neck 2004;26:796-807.
59. Wong RK, Jones GW, Sagar SM, Babjak AF, Whelan T. A Phase I-II study in the use of acupuncture-like transcutaneous nerve stimulation in the treatment of radiationinduced xerostomia in head-and-neck cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:472-80.
60. Wasserman TH, Brizel DM, Henke M, Monnier A, Eschwege F, Sauer R, et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 2005;63:985-90.
61. Navazesh M, Christensen CM. A comparison of whole mouth resting and stimulated salivary measurement procedures. J Dent Res 1982;61:1158-62.
62. Jones RE, Takeuchi T, Eisbruch A, D'Hondt E, Hazuka M, Ship JA. Ipsilateral parotid sparing study in head and neck cancer patients who receive radiation therapy: Results after 1 year. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;81:642-8.
63. Tylenda CA, Ship JA, Fox PC, Baum BJ. Evaluation of submandibular salivary flow rate in different age groups. J Dent Res 1988;67:1225-8 (Abstract).
64. Navazesh M. Methods for collecting saliva. Ann N Y Acad Sci 1993;694:72-7.
65. Burlage FR, Pijpe J, Coppes RP, Hemels ME, Meertens H, Canrinus A, et al. Variability of flow rate when collecting stimulated human parotid saliva. Eur J Oral Sci 2005;113:386-90.
66. Ericson S. An investigation of human parotid saliva secretion rate in response to different types of stimulation. Arch Oral Biol 1969;14:591-6.
67. Duran V, Dominguez P, Morales I, Lopez RO. Kinetic assessment of salivary secretory response to citric acid. Differences with pilocarpine. Rev Med Chil 1998;126:1330-7 (Abstract)
68. Amosson CM, Teh BS, Van TJ, Uy N, Huang E, Mai WY, et al. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique. Int J Radiat Oncol Biol Phys 2003;56:136-44.
69. Parliament MB, Scrimger RA, Anderson SG, Kurien EC, Thompson HK, Field GC, et al. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;58:663-73.
70. Roesink JM, Schipper M, Busschers W, Raaijmakers CP, Terhaard CH. A comparison of mean parotid gland dose with measures of parotid gland function after radiotherapy for head-and-neck cancer: Implications for future trials. Int J Radiat Oncol Biol Phys 2005;63:1006-9.
71. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:695-704.
72. Springer IN, Niehoff P, Warnke PH, Bocek G, Kovacs G, Suhr M, et al. Radiation caries-radiogenic destruction of dental collagen. Oral Oncol 2005;41:723-8.
73. Epstein JB, Lunn R, Le N, Stevenson-Moore P. Periodontal attachment loss in patients after head and neck radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:673-7.
74. Efficace F, Marrone R. Spiritual issues and quality of life assessment in cancer care. Death Stud 2002;26:743-56.
75. Larsson M, Hedelin B, Athlin E. Lived experiences of eating problems for patients with head and neck cancer during radiotherapy. J Clin Nurs 2003;12:562-70.
76. Bjordal K, Hammerlid E, Ahlner-Elmqvist M, de Graeff A, Boysen M, Evensen JF, et al. Quality of life in head and neck cancer patients: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 1999;17:1008-19.
77. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 1993;11:570-9.
78. Browman GP, Levine MN, Hodson DI, Sathya J, Russell R, Skingley P, et al. The Head and Neck Radiotherapy Questionnaire: A morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer. J Clin Oncol 1993;11:863-72.
79. King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996;5:555-67.
80. Pourel N, Peiffert D, Lartigau E, Desandes E, Luporsi E, Conroy T. Quality of life in long-term survivors of oropharynx carcinoma. Int J Radiat Oncol Biol Phys 2002;54:742-51.
81. Schwartz CE, Sprangers MA. Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Soc Sci Med 1999;48:1531-48.
82. Stephens RJ, Hopwood P, Girling DJ, Machin D. Randomized trials with quality of life endpoints: Are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 1997;6:225-36.
83. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol 2006;7:903-9.
84. Jensen K, Jensen AB, Grau C. The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires. Radiother Oncol 2006;78:298-305.
85. Jensen K, Jensen AB, Grau C. Smoking has a negative impact upon health related quality of life after treatment for head and neck cancer. Oral Oncol 2007 Feb;43(2):187-92. Epub 2006 Jul 24.
86. Meirovitz A, Murdoch-Kinch CA, Schipper M, Pan C, Eisbruch A. Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006;66:445-53.
87. Bjordal K, Freng A, Thorvik J, Kaasa S. Patient self-reported and clinician-rated quality of life in head and neck cancer patients: A cross-sectional study. Eur J Cancer B Oral Oncol 1995;31B:235-41.
88. Homsi J, Walsh D, Rivera N, Rybicki LA, Nelson KA, Legrand SB, et al. Symptom evaluation in palliative medicine: Patient report vs systematic assessment. Support Care Cancer 2006;14:444-53.
89. Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation therapy oncology group trial 98-01. J Clin Oncol 2005;23:2145-54.
90. Klepstad P, Hilton P, Moen J, Fougner B, Borchgrevink PC, Kaasa S. Self-reports are not related to objective assessments of cognitive function and sedation in patients with cancer pain admitted to a palliative care unit. Palliat Med 2002;16:513-9.
91. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 2004;22:3485-90.
92. Fang FM, Liu YT, Tang Y, Wang CJ, Ko SF. Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy. Cancer 2004;100:425-32.
93. de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur J Cancer 2001;37:332-9.
94. Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA. Health-related quality-of-life measurement in randomized clinical trials in breast cancer-taking stock. J Natl Cancer Inst 2003;95:263-81.
95. Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D'haese S, et al. Beyond the development of health-related quality-of-life (HRQOL) measures: A checklist for evaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 2003;21:3502-11.
96. Blazeby JM, Avery K, Sprangers M, Pikhart H, Fayers P, Donovan J. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol 2006;24:3178-86.
97. Bentzen SM, Vaeth M, Pedersen DE, Overgaard J. Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment . . . now! Int J Radiat Oncol Biol Phys 1995;32:1531-4.
98. Jung H, Beck-Bornholdt HP, Svoboda V, Alberti W, Herrmann T. Quantification of late complications after radiation therapy. Radiother Oncol 2001;61:233-46.
99. Jensen K, Grau C. Morbidity after Ipsilateral radiotherapy for oropharyngeal cancer. 2006 (submitted).
100. Jensen K, Jensen AB, Grau C. A cross sectional quality of life study of 116 recurrence free head and neck cancer patients. The first use of EORTC H&N35 in Danish. Acta Oncol 2006;45:28-37.
101. Braam PM, Roesink JM, Moerland MA, Raaijmakers CP, Schipper M, Terhaard CH. Long-term parotid gland function after radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:659-64.
102. Rademaker AW, Vonesh EF, Logemann JA, Pauloski BR, Liu D, Lazarus CL, et al. Eating ability in head and neck cancer patients after treatment with chemoradiation: A 12-month follow-up study accounting for dropout. Head Neck 2003;25:1034-41.
103. Allenby A, Matthews J, Beresford J, McLachlan SA. The application of computer touch-screen technology in screening for psychosocial distress in an ambulatory oncology setting. Eur J Cancer Care (Engl) 2002;11:245-53.
104. Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial. J Clin Oncol 2004;22:714-24.
105. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
106. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer 2000;88:2164-71.
107. D'Antonio LL, Zimmerman GJ, Cella DF, Long SA. Quality of life and functional status measures in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 1996;122:482-7.
108. Hassan SJ, Weymuller EA, Jr. Assessment of quality of life in head and neck cancer patients. Head Neck 1993;15:485-96.
109. Terrell JE, Nanavati KA, Esclamado RM, Bishop JK, Bradford CR, Wolf GT. Head and neck cancer-specific quality of life: Instrument validation. Arch Otolaryngol Head Neck Surg 1997;123:1125-32.
110. Henson BS, Inglehart MR, Eisbruch A, Ship JA. Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncol 2001;37:84-93.
111. Chen AY, Frankowski R, Bishop-Leone J, Hebert T, Leyk S, Lewin J, et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: The M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg 2001;127:870-6.
112. McHorney CA, Robbins J, Lomax K, Rosenbek JC, Chignell K, Kramer AE, et al. The SWAL-QOL and SWAL-CARE outcomes tool for oropharyngeal dysphagia in adults: III. Documentation of reliability and validity. Dysphagia 2002;17:97-114.
113. Taylor RJ, Chepeha JC, Teknos TN, Bradford CR, Sharma PK, Terrell JE, et al. Development and validation of the neck dissection impairment index: A quality of life measure. Arch Otolaryngol Head Neck Surg 2002;128:44-9